Biogen Stock Up On Buyback, Bull Note

A price-target hike from Jefferies is also helping BIIB

Managing Editor
Dec 20, 2019 at 10:09 AM
facebook twitter linkedin

The shares of Biogen Inc (NASDAQ:BIIB) are up 0.9% to trade at $300.18 this morning, after the drugmaker announced a $5 billion share repurchase program. This is the second $5 billion stock buyback Biogen has issued in 2019. Also fueling today's price action is a price-target hike from Jefferies $325 from $310, territory not charted since March. 

Despite today's upside move, Biogen stock remains stuck below year-to-date breakeven level. But the shares are still up 28% this quarter, thanks to a huge October bull gap in response to upbeat results from the company's Alzheimer Disease treatment

The majority of analysts are entrenched in the bearish camp, with 17 of the 25 in coverage doling out "hold" or worse ratings. Plus, the consensus 12-month price target of $303.29 is in line to its current perch. In other words, a shift in analyst attention could provide short-term tailwinds for the equity.

Options are an intriguing vehicle to bet on Biogen. The stock's Schaeffer's Volatility Index (SVI) of 26% sits in the 7th percentile of its annual range. This means the stock's short-term options are pricing in extremely low volatility expectations right now. 


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 


300x250 - Banner 3 - v1